Trial Search Results

Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy

This randomized, pilot phase I trial studies whether phone or email reminders increases vaginal dilator use in patients with endometrial, cervical, or vaginal cancers after they undergo brachytherapy. Brachytherapy is a type of internal radiation which uses radioactive material placed directly into or near a tumor to kill tumor cells. A reminder program may help increase use of vaginal dilators and decrease long-term side effects following brachytherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Other: survey administration
  • Other: computer-assisted intervention
  • Behavioral: telephone-based intervention


Phase 1


Inclusion Criteria:

   - Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of
   their treatment

   - Patients cannot have previously received pelvic external beam radiation or
   brachytherapy. Patients may be enrolled while undergoing vaginal brachytherapy
   radiation treatment.

   - Patients should have a life expectancy of at least 1 year

   - No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status

   - No organ and marrow function requirements

   - Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

   - Patients who have received prior pelvic external beam radiation or brachytherapy will
   be excluded

   - No restrictions regarding use of other investigational agents

   - No exclusion requirements due to co-morbid disease or intercurrent illness

   - No investigational agent, so no exclusion requirements regarding history of allergic
   reactions attributed to compounds of similar chemical or biologic composition to
   investigational agent or device

   - No exclusion criteria relating to concomitant medications

   - No exclusion criteria for pregnant or nursing patients from participating in this
   study (Of note, pregnant patients will not be treated with vaginal brachytherapy, a
   requirement for enrolling on this study)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Dylann Fujimoto